Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Delta Research Partners LLC

Neither a doctor nor a teaching hospital

Research payments

$3,889,634

355 payments

Through program year 2025, Delta Research Partners LLC is reported as receiving $3,889,634 in research payments, across 355 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $642,423 86
2024 Research $649,194 176
2023 Research $435,822 35
2022 Research $586,604 10
2021 Research $530,841 12
2020 Research $516,804 13
2019 Research $527,945 23

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eli Lilly and Company $2,307,790 67 payments
  2. Madrigal Pharmaceuticals $598,183 76 payments
  3. GlaxoSmithKline, LLC. $449,277 167 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $441,671 4 payments
  5. Braintree Laboratories, Inc. $43,442 26 payments
  6. Janssen Research & Development, LLC $31,732 2 payments
  7. Novo Nordisk AS $16,316 12 payments
  8. Ironwood Pharmaceuticals, Inc $1,225 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis Lucent 3 $1,232,984 12 payments
  2. A 52-Week, Phase 3, Open-Label Extension Study, With a Double-blind Lead-in, to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE) $521,489 49 payments
  3. 17 B-Hydroxysteroid Dehydrogenase Type 13 Minimization for the Treatme $449,277 167 payments
  4. POCC in NASH $441,671 4 payments
  5. A Phase 3, Multicenter, Open Label, Long Term Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Crohns Disease $225,037 11 payments
  6. A Phase 2 Multicenter Randomized Parallel-Arm Placebo-Controlled Study of Ly3074828 in Subjects With Active Crohns Disease (Serenity) $179,095 5 payments
  7. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease $175,364 10 payments
  8. A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (Lucent 1) $140,994 7 payments
  9. A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (Lucent 2) $132,001 7 payments
  10. A Phase 3 Multicenter Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis Lucent 3 $108,907 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record